These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35687965)

  • 1. Non-bacterial cystitis secondary to pembrolizumab: A case report and review of the literature.
    He X; Tu R; Zeng S; He Z; Liu S; Fang Y
    Curr Probl Cancer; 2022 Aug; 46(4):100863. PubMed ID: 35687965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Case Report of Non-Bacterial Cystitis Caused by Immune Checkpoint Inhibitors.
    Zhu S; Bian L; Lv J; Liu B; Shen J
    Front Immunol; 2021; 12():788629. PubMed ID: 35003107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-bacterial cystitis caused by pembrolizumab therapy for adenocarcinoma of the lung: a case report.
    Di C; Yu T; Ni L
    Front Immunol; 2024; 15():1423123. PubMed ID: 39034999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report.
    Shen L; Chen H; Wei Q
    Front Immunol; 2021; 12():621858. PubMed ID: 33936037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent Cystitis Associated With 2 Programmed Death 1 Inhibitors: A Rare Case Report and Literature Review.
    Fan Y; Zhao J; Mi Y; Zhang Z; Geng Y; Zhou L; Shen L; Zhang Z
    J Immunother; 2023 Nov-Dec 01; 46(9):341-345. PubMed ID: 37721343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
    Thomas S; Bae C; Joy-Ann T; Traverse W
    J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
    Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
    JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
    Yin B; Xiao J; Li J; Liu X; Wang J
    J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
    Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
    J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune-related ureteritis and cystitis induced by immune checkpoint inhibitors: Case report and literature review.
    Li J; Yu YF; Qi XW; Du Y; Li CQ
    Front Immunol; 2022; 13():1051577. PubMed ID: 36685488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience.
    Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F
    Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
    JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delayed immune-related neutropenia with hepatitis by pembrolizumab.
    Nakako S; Nakashima Y; Okamura H; Tani Y; Ueda T; Makuuchi Y; Kuno M; Takakuwa T; Nishimoto M; Koh H; Nakamae H; Hino M
    Immunotherapy; 2022 Feb; 14(2):101-105. PubMed ID: 34758635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed immune-related hepatitis after 24 months of pembrolizumab treatment: a case report and literature review.
    Salazar González F; Quiñones Palacios CA; Manzaneque Gordón A; Mazarico Gallego JM; Díaz A; Molas Ferrer G
    Anticancer Drugs; 2024 Mar; 35(3):284-287. PubMed ID: 37948346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature.
    Zhou Q; Qin Z; Yan P; Wang Q; Qu J; Chen Y
    Front Immunol; 2023; 14():1226993. PubMed ID: 37869004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: A case report.
    Hamada K; Yoshimura K; Oshinomi K; Hirasawa Y; Ariizumi H; Ohkuma R; Shida M; Kubota Y; Matsui H; Ishiguro T; Sambe T; Ishida H; Horiike A; Wada S; Iwamoto S; Uchida N; Ogawa Y; Kobayashi S; Tsunoda T
    Medicine (Baltimore); 2022 Jan; 101(2):e28339. PubMed ID: 35029177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma.
    Zhao JJ; Wen XZ; Ding Y; Li DD; Zhu BY; Li JJ; Weng DS; Zhang X; Zhang XS
    Aging (Albany NY); 2020 Jun; 12(11):10663-10675. PubMed ID: 32516130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
    Cortellini A; Friedlaender A; Banna GL; Porzio G; Bersanelli M; Cappuzzo F; Aerts JGJV; Giusti R; Bria E; Cortinovis D; Grossi F; Migliorino MR; Galetta D; Passiglia F; Berardi R; Mazzoni F; Di Noia V; Signorelli D; Tuzi A; Gelibter A; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Inno A; Di Marino P; Mansueto G; Zoratto F; Santoni M; Tudini M; Ghidini M; Filetti M; Catino A; Pizzutilo P; Sala L; Occhipinti MA; Citarella F; Russano M; Torniai M; Cantini L; Follador A; Sforza V; Nigro O; Ferrara MG; D'Argento E; Leonetti A; Pettoruti L; Antonuzzo L; Scodes S; Landi L; Guaitoli G; Baldessari C; Bertolini F; Della Gravara L; Dal Bello MG; Belderbos RA; De Filippis M; Cecchi C; Ricciardi S; Donisi C; De Toma A; Proto C; Addeo A; Cantale O; Ricciuti B; Genova C; Morabito A; Santini D; Ficorella C; Cannita K
    Clin Lung Cancer; 2020 Nov; 21(6):498-508.e2. PubMed ID: 32680806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.